Lu Yao
Peking University
21 Papers
49 Citations
Lu Yao is an academic researcher from Peking University. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 6, co-authored 10 publications.
Chat about Author
Papers
RAD51C germline mutations in Chinese women with familial breast cancer.
Zhiyuan Pang,Lu Yao,Juan Zhang,Tao Ouyang,Jinfeng Li,Tianfeng Wang,Zhaoqing Fan,Tie Fan,Benyao Lin,Yuntao Xie +9 more
TL;DR: This study screened the entire coding regions and exon–intron boundaries of the RAD51C gene in 273 Chinese women with familial breast cancer who do not carry mutations in BRCA1 and BRCa2 genes by polymerase chain reaction (PCR)-sequencing and detected eight germline sequence variants in the RAD 51C gene.
33
Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer.
Shuyan Sheng,Ye Xu,Yonghai Guo,Lu Yao,Li Hu,Tao Ouyang,Jinfeng Li,Tianfeng Wang,Zhaoqing Fan,Tie Fan,Benyao Lin,Yuntao Xie +11 more
TL;DR: It is suggested that TP53 germline mutations occur more frequently in very early onset unselected breast cancer patients; and TP53 Germline mutation carriers have a very poor survival and may benefit from carboplatin‐based neoadjuvant chemotherapy in unselected Breast cancer patients.
20
Breast cancer subtypes and survival in Chinese women with operable primary breast cancer
Zhao-sheng Li,Lu Yao,Yiqiang Liu,Tao Ouyang,Jinfeng Li,Tianfeng Wang,Zhaoqing Fan,Tie Fan,Benyao Lin,Yuntao Xie +9 more
TL;DR: Luminal A (ER+ and/or PR+, HER2-) had a favorable disease-free survival (DFS) and overall survival (OS) compared with other subtypes in the entire cohort, but this is not the case in patients with lymph node negative disease; triple-negative subtype has a worse survival in both lymph node positive and lymph nodes negative patients.
A genome-wide association study identifies WT1 variant with better response to 5-fluorouracil, pirarubicin and cyclophosphamide neoadjuvant chemotherapy in breast cancer patients
Lina Wu,Lu Yao,Hong Zhang,Tao Ouyang,Jinfeng Li,Tianfeng Wang,Zhaoqing Fan,Tie Fan,Benyao Lin,Cameron C. Yin,Yuntao Xie +10 more
TL;DR: Results suggest that WT1, located in the WT1 gene, may be a potential target of anthracycline-based neoadjuvant therapy for breast cancer.
11
Clinical relevance of pathogenic germline variants in mismatch repair genes in Chinese breast cancer patients
Lin Hu,Jie Sun,Zhongwu Liu,Ziwei Qu,Yan Liu,Qiting Wan,Jia-Ming Liu,X. Ding,Fang Zang,Juan Zhang,Lu Yao,Ye Xu,Yin Wang,Yuntao Xie +13 more
TL;DR: Wang et al. as discussed by the authors investigated the prevalence and clinical relevance of pathogenic germline variants in MMR genes in large series of breast cancers and found that MMR variant carriers might have worse recurrence-free survival compared with non-carriers.